JP6654574B2 - Ｃｂ２アゴニストとして有用なピリジン−２−アミド - Google Patents
Ｃｂ２アゴニストとして有用なピリジン−２−アミド Download PDFInfo
- Publication number
- JP6654574B2 JP6654574B2 JP2016560674A JP2016560674A JP6654574B2 JP 6654574 B2 JP6654574 B2 JP 6654574B2 JP 2016560674 A JP2016560674 A JP 2016560674A JP 2016560674 A JP2016560674 A JP 2016560674A JP 6654574 B2 JP6654574 B2 JP 6654574B2
- Authority
- JP
- Japan
- Prior art keywords
- carboxamide
- pyridine
- cyclopropylmethoxy
- cyclopropyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 **C(*C(C(*(*)*)=O)=C*1)=C1*=C Chemical compound **C(*C(C(*(*)*)=O)=C*1)=C1*=C 0.000 description 3
- AACOHRTWARDWLJ-QURGRASLSA-N CC(C)(C)OC(CNC(C)(C)CC(/N=N/C(c(cc1)ccc1F)=O)=O)=O Chemical compound CC(C)(C)OC(CNC(C)(C)CC(/N=N/C(c(cc1)ccc1F)=O)=O)=O AACOHRTWARDWLJ-QURGRASLSA-N 0.000 description 1
- GHYILXDIRFBXHB-UHFFFAOYSA-N CC(C)(CO)c1n[o]c(NC(c2nc(OCC3CC3)c(C3CC3)cc2)=O)c1 Chemical compound CC(C)(CO)c1n[o]c(NC(c2nc(OCC3CC3)c(C3CC3)cc2)=O)c1 GHYILXDIRFBXHB-UHFFFAOYSA-N 0.000 description 1
- FHZJQDSZRHZNEW-UHFFFAOYSA-N CC(C)(Cc1nc(-c2ccccc2)n[o]1)NC(c1cccc(OCCOC)n1)=O Chemical compound CC(C)(Cc1nc(-c2ccccc2)n[o]1)NC(c1cccc(OCCOC)n1)=O FHZJQDSZRHZNEW-UHFFFAOYSA-N 0.000 description 1
- ZKIQRLLFDHOMPH-UHFFFAOYSA-N CC(C)(Cc1nnc(-c2ccccc2)[o]1)NC(c1nc(-c2cccc(Cl)c2)ccc1)=O Chemical compound CC(C)(Cc1nnc(-c2ccccc2)[o]1)NC(c1nc(-c2cccc(Cl)c2)ccc1)=O ZKIQRLLFDHOMPH-UHFFFAOYSA-N 0.000 description 1
- ICZZEKXESKXQMC-UHFFFAOYSA-N CC(C)(Cc1nnc(C2CC2)[o]1)NC(c1nc(-c(cc2)ccc2Cl)ccc1)=O Chemical compound CC(C)(Cc1nnc(C2CC2)[o]1)NC(c1nc(-c(cc2)ccc2Cl)ccc1)=O ICZZEKXESKXQMC-UHFFFAOYSA-N 0.000 description 1
- OGVLKWOXRIUUHO-UHFFFAOYSA-N CCOCCOCC(C)(C)c1n[o]c(NC(c2nc(OCC3CC3)c(C3CC3)cc2)=O)c1 Chemical compound CCOCCOCC(C)(C)c1n[o]c(NC(c2nc(OCC3CC3)c(C3CC3)cc2)=O)c1 OGVLKWOXRIUUHO-UHFFFAOYSA-N 0.000 description 1
- JCYMMWGAKHJJQJ-CYBMUJFWSA-N NC([C@@H](CSCC1)N1C(c1nc(OCC2CC2)c(C2CC2)nc1)=O)=O Chemical compound NC([C@@H](CSCC1)N1C(c1nc(OCC2CC2)c(C2CC2)nc1)=O)=O JCYMMWGAKHJJQJ-CYBMUJFWSA-N 0.000 description 1
- GEAUZHDIOVUSBN-UHFFFAOYSA-N Nc(c(OCC1CC1)n1)ncc1Br Chemical compound Nc(c(OCC1CC1)n1)ncc1Br GEAUZHDIOVUSBN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14163555.7 | 2014-04-04 | ||
| EP14163555 | 2014-04-04 | ||
| PCT/EP2015/057151 WO2015150440A1 (en) | 2014-04-04 | 2015-04-01 | Pyridine-2-amides useful as cb2 agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509676A JP2017509676A (ja) | 2017-04-06 |
| JP2017509676A5 JP2017509676A5 (enExample) | 2019-05-16 |
| JP6654574B2 true JP6654574B2 (ja) | 2020-02-26 |
Family
ID=50424143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016560674A Expired - Fee Related JP6654574B2 (ja) | 2014-04-04 | 2015-04-01 | Ｃｂ２アゴニストとして有用なピリジン−２−アミド |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20160376262A1 (enExample) |
| EP (1) | EP3126359A1 (enExample) |
| JP (1) | JP6654574B2 (enExample) |
| KR (1) | KR20160142365A (enExample) |
| CN (1) | CN106132958A (enExample) |
| AR (1) | AR099933A1 (enExample) |
| AU (1) | AU2015239539A1 (enExample) |
| CA (1) | CA2943013A1 (enExample) |
| CL (1) | CL2016002483A1 (enExample) |
| CR (1) | CR20160448A (enExample) |
| EA (1) | EA030116B1 (enExample) |
| IL (1) | IL247817A0 (enExample) |
| MA (1) | MA39843A (enExample) |
| MX (1) | MX2016012689A (enExample) |
| PE (1) | PE20161370A1 (enExample) |
| PH (1) | PH12016501865A1 (enExample) |
| SG (2) | SG11201608108SA (enExample) |
| TW (1) | TW201623276A (enExample) |
| WO (1) | WO2015150440A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2978755T3 (enExample) | 2013-03-26 | 2018-06-02 | ||
| EP3126354B1 (en) | 2014-04-04 | 2020-01-22 | H. Lundbeck A/S | Halogenated quinazolin-thf-amines as pde1 inhibitors |
| PE20181203A1 (es) * | 2015-12-09 | 2018-07-23 | Hoffmann La Roche | Derivados de fenilo como agonistas de receptor de cannabinoides 2 |
| BR112018068681A2 (pt) | 2016-03-16 | 2019-01-15 | Bayer Cropscience Ag | derivados de n-(cianobenzil)-6-(ciclopropil-carbonilamino)-4-(fenil)-piridina-2-carboxamida e compostos relacionados como pesticidas e agentes de proteção de plantas |
| AR112199A1 (es) | 2017-06-20 | 2019-10-02 | Hoffmann La Roche | Derivados de piridina como agonistas inversos del receptor cannabinoide 2 |
| SG11202009103WA (en) * | 2018-06-27 | 2020-10-29 | Hoffmann La Roche | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| EP3814328A1 (en) | 2018-06-27 | 2021-05-05 | F. Hoffmann-La Roche AG | Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| WO2020002314A1 (en) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Radiolabeled cannabinoid receptor 2 ligand |
| EP3814337B1 (en) * | 2018-06-27 | 2025-05-14 | F. Hoffmann-La Roche AG | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2601575A1 (en) | 2005-03-31 | 2006-10-05 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
| FR2887550A1 (fr) | 2005-06-24 | 2006-12-29 | Sanofi Aventis Sa | Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique |
| WO2008141239A1 (en) * | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors |
| EP2311443A1 (en) | 2009-10-15 | 2011-04-20 | Rheinische Friedrich-Wilhelms-Universität | Pharmaceutical composition containing cannabinoid-receptor 2 antagonists |
| WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
| US9512141B2 (en) * | 2012-12-07 | 2016-12-06 | Hoffmann-La Roche Inc. | Pyrazine derivatives as CB2 receptor agonists |
| CA2885987A1 (en) * | 2012-12-07 | 2014-06-12 | F. Hoffmann-La Roche Ag | Pyridine-2-amides useful as cb2 agonists |
-
2015
- 2015-04-01 MA MA039843A patent/MA39843A/fr unknown
- 2015-04-01 CA CA2943013A patent/CA2943013A1/en not_active Abandoned
- 2015-04-01 CR CR20160448A patent/CR20160448A/es unknown
- 2015-04-01 EA EA201691983A patent/EA030116B1/ru not_active IP Right Cessation
- 2015-04-01 JP JP2016560674A patent/JP6654574B2/ja not_active Expired - Fee Related
- 2015-04-01 MX MX2016012689A patent/MX2016012689A/es unknown
- 2015-04-01 SG SG11201608108SA patent/SG11201608108SA/en unknown
- 2015-04-01 EP EP15713492.5A patent/EP3126359A1/en not_active Withdrawn
- 2015-04-01 KR KR1020167030780A patent/KR20160142365A/ko not_active Withdrawn
- 2015-04-01 CN CN201580017199.1A patent/CN106132958A/zh active Pending
- 2015-04-01 PE PE2016001656A patent/PE20161370A1/es unknown
- 2015-04-01 WO PCT/EP2015/057151 patent/WO2015150440A1/en not_active Ceased
- 2015-04-01 AU AU2015239539A patent/AU2015239539A1/en not_active Abandoned
- 2015-04-01 AR ARP150100985A patent/AR099933A1/es unknown
- 2015-04-01 SG SG10201809066TA patent/SG10201809066TA/en unknown
- 2015-04-02 TW TW104111026A patent/TW201623276A/zh unknown
-
2016
- 2016-09-09 US US15/260,826 patent/US20160376262A1/en not_active Abandoned
- 2016-09-14 IL IL247817A patent/IL247817A0/en unknown
- 2016-09-22 PH PH12016501865A patent/PH12016501865A1/en unknown
- 2016-09-30 CL CL2016002483A patent/CL2016002483A1/es unknown
-
2018
- 2018-07-24 US US16/044,320 patent/US20180327396A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN106132958A (zh) | 2016-11-16 |
| US20160376262A1 (en) | 2016-12-29 |
| EA030116B1 (ru) | 2018-06-29 |
| PH12016501865A1 (en) | 2016-12-19 |
| EP3126359A1 (en) | 2017-02-08 |
| IL247817A0 (en) | 2016-11-30 |
| SG10201809066TA (en) | 2018-11-29 |
| CL2016002483A1 (es) | 2017-03-10 |
| WO2015150440A1 (en) | 2015-10-08 |
| EA201691983A1 (ru) | 2017-01-30 |
| AU2015239539A1 (en) | 2016-09-29 |
| CR20160448A (es) | 2016-12-14 |
| MA39843A (fr) | 2017-02-08 |
| MX2016012689A (es) | 2016-12-14 |
| AR099933A1 (es) | 2016-08-31 |
| CA2943013A1 (en) | 2015-10-08 |
| TW201623276A (zh) | 2016-07-01 |
| US20180327396A1 (en) | 2018-11-15 |
| SG11201608108SA (en) | 2016-10-28 |
| PE20161370A1 (es) | 2016-12-17 |
| KR20160142365A (ko) | 2016-12-12 |
| JP2017509676A (ja) | 2017-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6654574B2 (ja) | Ｃｂ２アゴニストとして有用なピリジン−２−アミド | |
| DK2928881T3 (en) | Hitherto unknown pyridine derivatives | |
| EP3126349B1 (en) | 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists | |
| US20220064178A1 (en) | Pyridine derivatives | |
| HK1227396A1 (en) | Pyridine-2-amides useful as cb2 agonists | |
| TW201326139A (zh) | 新穎吡□衍生物 | |
| HK1228903A1 (en) | 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists | |
| HK40019933A (en) | Pyridine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180326 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181025 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181113 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190201 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20190403 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190618 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190911 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200107 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200130 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6654574 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |